{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:58:54Z","timestamp":1790794734576,"version":"4.1.0"},"reference-count":38,"publisher":"Begell House","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Crit Rev Immunol"],"published-print":{"date-parts":[[2026]]},"abstract":"<p>This study delves into effective therapeutic strategies for endometrial cancer, focusing on the distinct functions of primary NK cells and supercharged NK (sNK) cells in targeting endometrial tumors. The research utilized AN3CA and HEC1B tumors to highlight the differences in efficacy between the two cell types. Notably, sNK cells exhibited the ability to target both stem-like AN3CA and well-differentiated HEC-1B tumors, while primary NK cells targeted the stem-like tumors exclusively. To demonstrate the &lt;i&gt;in vivo&lt;\/i&gt; effectiveness of sNK cells, AN3CA tumors were implanted in the uterus of humanized-BLT (hu-BLT) mice, followed by sNK cell therapy. The results showed that a single infusion of sNK cells significantly reduced tumor burden and restored immune cell function in the hu-BLT mice. This outcome underscores the potential of sNK therapy in eliminating stem-like, poorly differentiated, and well-differentiated tumors, while also enhancing the function of endogenous NK cells to better manage remaining tumors in patients. The findings of this study suggest that innovative treatments like sNK cell therapy represent the future of uterine cancer treatment, offering new avenues for effectively addressing the complexity of this disease.<\/p>","DOI":"10.1615\/critrevimmunol.2025060654","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T13:48:57Z","timestamp":1755092937000},"page":"25-36","source":"Crossref","is-referenced-by-count":0,"title":["Supercharged NK Cells: A Novel NK Cell-Based Immunotherapy to Target Poorly Differentiated and Well-Differentiated Uterine Cancers"],"prefix":"10.1615","volume":"46","author":[{"given":"Edward","family":"Sher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara-Huerta","family":"Yepez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Chun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anahid","family":"Jewett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kawaljit","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"613","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet. 2005;366(9484):491\u2013505.","DOI":"10.1016\/S0140-6736(05)67063-8"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Crosbie EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, Powell ME, Singh N. Endometrial cancer. Lancet. 2022;399(10333):1412\u201328.","DOI":"10.1016\/S0140-6736(22)00323-3"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Felix AS, Weissfeld JL, Stone RA, Bowser R, Chivukula M, Edwards RP, Linkov F. Factors associated with type I and type II endometrial cancer. Cancer Causes Control. 2010;21(11):1851\u20136.","DOI":"10.1007\/s10552-010-9612-8"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Xue Q, Che W, Xue L, Zhang X, Wang X, Lyu J. Causes of death in endometrial cancer survivors: A surveillance, epidemiology, and end result-based analysis. Cancer Med. 2023;12(9):10917\u201330.","DOI":"10.1002\/cam4.5804"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Wang Y, Yang D, Cogdell D, Hu L, Xue F, Broaddus R, Zhang W. Genomic characterization of gene copy-number aberrations in endometrial carcinoma cell lines derived from endometrioid-type endometrial adenocarcinoma. Technol Cancer Res Treat. 2010;9(2): 179\u201389.","DOI":"10.1177\/153303461000900207"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Van Nyen T, Moiola CP, Colas E, Annibali D, Amant F. Modeling endometrial cancer: Past, present, and future. Int J Mol Sci. 2018;19(8):2348.","DOI":"10.3390\/ijms19082348"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Moretta A, Marcenaro E, Parolini S, Ferlazzo G, Moretta L. NK cells at the interface between innate and adaptive immunity. Cell Death Differ. 2008;15(2):226\u201333.","DOI":"10.1038\/sj.cdd.4402170"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S. Innate or adaptive immunity? The example of natural killer cells. Science. 2011;331(6013):44\u20139.","DOI":"10.1126\/science.1198687"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Colucci F, Caligiuri MA, Di Santo JP. What does it take to make a natural killer? Nat Rev Immunol. 2003;3(5):413\u201325.","DOI":"10.1038\/nri1088"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol. 2001;22(11):633\u201340.","DOI":"10.1016\/S1471-4906(01)02060-9"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Farag SS, Caligiuri MA. Human natural killer cell development and biology. Blood Rev. 2006;20(3):123\u201337.","DOI":"10.1016\/j.blre.2005.10.001"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Sun H, Sun C, Tian Z, Xiao W. NK cells in immunotolerant organs. Cell Mol Immunol. 2013;10(3):202\u201312.","DOI":"10.1038\/cmi.2013.9"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Bui VT, Tseng H-C, Kozlowska A, Maung PO, Kaur K, Topchyan P, Jewett A. Augmented IFN-\u03b3 and TNF-\u03b1 induced by probiotic bacteria in NK cells mediate differentiation of stem-like tumors leading to inhibition of tumor growth and reduction in inflammatory cytokine release; regulation by IL-10. Front Immunol. 2015;6:576.","DOI":"10.3389\/fimmu.2015.00576"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Kaur K, Topchyan P, Kozlowska AK, Ohanian N, Chiang J, Maung PO, Park SH, Ko MW, Fang C, Nishimura I, Jewett A. Super-charged NK cells inhibit growth and progression of stem-like\/poorly differentiated oral tumors in vivo in humanized BLT mice; effect on tumor differentiation and response to chemotherapeutic drugs. Oncoimmunology. 2018;7(5):e1426518.","DOI":"10.1080\/2162402X.2018.1426518"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Kaur K, Kozlowska AK, Topchyan P, Ko M-W, Ohanian N, Chiang J, Cook J, Maung PO, Park SH, Cacalano N, Fang C, Jewett A. Probiotic-treated super-charged NK cells efficiently clear poorly differentiated pancreatic tumors in Hu-BLT mice. Cancers. 2020;12(1):63.","DOI":"10.3390\/cancers12010063"},{"key":"16","unstructured":"Sillem M, Prifti S, Koumouridis A, Runnebaum B. Invasiveness corresponds to differentiation rather than to proteinase secretion in endometrial cancer cell lines. Eur J Gynaecol Oncol. 1999;20(5\u20136):367\u201370."},{"key":"17","doi-asserted-by":"crossref","unstructured":"Zhang C, Wang R, Li M, Yang Q. Long non coding RNA BLACAT2\/miR 378a 3p\/YY1 feedback loop promotes the proliferation, migration and invasion of uterine corpus endometrial carcinoma. Oncol Rep. 2023;49(5):108.","DOI":"10.3892\/or.2023.8544"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Kaur K, Nanut MP, Ko M-W, Safaie T, Kos J, Jewett A. Natural killer cells target and differentiate cancer stemlike cells\/undifferentiated tumors: Strategies to optimize their growth and expansion for effective cancer immunotherapy. Curr Opin Immunol. 2018;51:170\u201380.","DOI":"10.1016\/j.coi.2018.03.022"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Glaab WE, Risinger JI, Umar A, Kunkel TA, Barrett JC, Tindall KR. Characterization of distinct human endometrial carcinoma cell lines deficient in mismatch repair that originated from a single tumor. J Biol Chem. 1998;273(41):26662-9.","DOI":"10.1074\/jbc.273.41.26662"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Kaur K, Cook J, Park S-H, Topchyan P, Kozlowska A, Ohanian N, Fang C, Nishimura I, Jewett A. Novel strategy to expand super-charged NK cells with significant potential to lyse and differentiate cancer stem cells: Differences in NK expansion and function between healthy and cancer patients. Front Immunol. 2017;8:297.","DOI":"10.3389\/fimmu.2017.00297"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Kaur K, Chen P-C, Ko M-W, Mei A, Senjor E, Malarkannan S, Kos J, Jewett A. Sequential therapy with supercharged NK cells with either chemotherapy drug cisplatin or anti-PD-1 antibody decreases the tumor size and significantly enhances the NK function in Hu-BLT mice. Front Immunol. 2023;14:1132807.","DOI":"10.3389\/fimmu.2023.1132807"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Chovatiya N, Kaur K, Huerta-Yepez S, Chen P-C, Neal A, DiBernardo G, Gumrukcu S, Memarzadeh S, Jewett A. Inability of ovarian cancers to upregulate their MHCclass I surface expression marks their aggressiveness and increased susceptibility to NK cell-mediated cytotoxicity. Cancer Immunol Immunother. 2022;71(12):2929\u201341.","DOI":"10.1007\/s00262-022-03192-7"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Kaur K, Safaie T, Ko M-W, Wang Y, Jewett A. ADCC against MICA\/B is mediated against differentiated oral and pancreatic and not stem-like\/poorly differentiated tumors by the NK cells; loss in cancer patients due to down-modulation of CD16 receptor. Cancers. 2021;13(2):239.","DOI":"10.3390\/cancers13020239"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Kaur K, Ko M-W, Ohanian N, Cook J, Jewett A. Osteoclast-expanded super-charged NK-cells preferentially select and expand CD8+ T cells. Sci Rep. 2020;10(1):20363.","DOI":"10.1038\/s41598-020-76702-1"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Tseng HC, Inagaki A, Bui VT, Cacalano N, Kasahara N, Man YG, Jewett A. Differential targeting of stem cells and differentiated glioblastomas by NK cells. J Cancer. 2015;6(9):866\u201376.","DOI":"10.7150\/jca.11527"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Jewett A, Wang MY, Teruel A, Poupak Z, Bostanian Z, Park NH. Cytokine dependent inverse regulation of CD54 (ICAM1) and major histocompatibility complex class I antigens by nuclear factor kappaB in HEp2 tumor cell line: Effect on the function of natural killer cells. Hum Immunol. 2003;64(5):505\u201320.","DOI":"10.1016\/S0198-8859(03)00039-9"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Jewett A, Bonavida B. Target-induced inactivation and cell death by apoptosis in a subset of human NK cells. J Immunol. 1996;156(3):907\u201315.","DOI":"10.4049\/jimmunol.156.3.907"},{"key":"28","doi-asserted-by":"crossref","unstructured":"Nguyen T, Chen PC, Pham J, Kaur K, Raman SS, Jewett A, Chiang J. Current and future states of natural killer cellbased immunotherapy in hepatocellular carcinoma. Crit Rev Immunol. 2024;44(5):71\u201385.","DOI":"10.1615\/CritRevImmunol.2024052486"},{"key":"29","doi-asserted-by":"crossref","unstructured":"Jewett A, Kos J, Fong Y, Ko MW, Safaei T, Peri\u0161i\u0107 Nanut M, Kaur K. NK cells shape pancreatic and oral tumor microenvironments; role in inhibition of tumor growth and metastasis. Semin Cancer Biol. 2018;53:178\u201388.","DOI":"10.1016\/j.semcancer.2018.08.001"},{"key":"30","doi-asserted-by":"crossref","unstructured":"Kaur K, Jewett A. Supercharged NK cell-based immuotherapy in humanized bone marrow liver and thymus (Hu-BLT) mice model of oral, pancreatic, glioblastoma, hepatic, melanoma and ovarian cancers. Crit Rev Immunol. 2023;43(2):13\u201325.","DOI":"10.1615\/CritRevImmunol.2023050618"},{"key":"31","doi-asserted-by":"crossref","unstructured":"Chiang J, Chen PC, Pham J, Nguyen CQ, Kaur K, Raman SS, Jewett A. Characterizing hepatocellular carcinoma stem markers and their corresponding susceptibility to NK-cell based immunotherapy. Front Immunol. 2023;14:1284669.","DOI":"10.3389\/fimmu.2023.1284669"},{"key":"32","doi-asserted-by":"crossref","unstructured":"Kaur K, Kozlowska AK, Topchyan P, Ko MW, Ohanian N, Chiang J, Cook J, Maung PO, Park SH, Cacalano N, Fang C, Jewett A. Probiotic-treated super-charged NK cells efficiently clear poorly differentiated pancreatic tumors in Hu-BLT mice. Cancers. 2019;12(1):63.","DOI":"10.3390\/cancers12010063"},{"key":"33","doi-asserted-by":"crossref","unstructured":"Kaur K, Topchyan P, Kozlowska AK, Ohanian N, Chiang J, Maung PO, Park SH, Ko MW, Fang C, Nishimura I, Jewett A. Super-charged NK cells inhibit growth and progression of stem-like\/poorly differentiated oral tumors in vivo in humanized BLT mice; effect on tumor differentiation and response to chemotherapeutic drugs. Oncoimmunology. 2018;7(5):e1426518.","DOI":"10.1080\/2162402X.2018.1426518"},{"key":"34","doi-asserted-by":"crossref","unstructured":"Kozlowska AK, Tseng HC, Kaur K, Topchyan P, Inagaki A, Bui VT, Kasahara N, Cacalano N, Jewett A. Resistance to cytotoxicity and sustained release of interleukin-6 and interleukin-8 in the presence of decreased interferon-\u03b3 after differentiation of glioblastoma by human natural killer cells. Cancer Immunol Immunother. 2016;65(9): 1085\u201397.","DOI":"10.1007\/s00262-016-1866-x"},{"key":"35","doi-asserted-by":"crossref","unstructured":"Kozlowska AK, Topchyan P, Kaur K, Tseng HC, Teruel A, Hiraga T, Jewett A. Differentiation by NK cells is a prerequisite for effective targeting of cancer stem cells\/poorly differentiated tumors by chemopreventive and chemotherapeutic drugs. J Cancer. 2017;8(4):537\u201354.","DOI":"10.7150\/jca.15989"},{"key":"36","doi-asserted-by":"crossref","unstructured":"Kaur K, Celis AP, Jewett A. Natural killer cell-secreted IFN-\u03b3 and TNF-\u03b1 mediated differentiation in lung stem-like tumors, leading to the susceptibility of the tumors to chemotherapeutic drugs. Cells. 2025;14(2):90.","DOI":"10.3390\/cells14020090"},{"key":"37","doi-asserted-by":"crossref","unstructured":"Ko MW, Mei A, Senjor E, Nanut MP, Gao LW, Wong P, Chen PC, Cohn W, Whitelegge JP, Kos J, Kaur K, Malarkannan S, Jewett A. Osteoclast-expanded supercharged NK cells perform superior antitumour effector functions. BMJ Oncol. 2025;4(1):e000676.","DOI":"10.1136\/bmjonc-2024-000676"},{"key":"38","doi-asserted-by":"crossref","unstructured":"Kaur K, Topchyan P, Jewett A. Supercharged natural killer (sNK) cells inhibit melanoma tumor progression and restore endogenous NK cell function in humanized BLT mice. Cancers. 2025;17(15):2430.","DOI":"10.3390\/cancers17152430"}],"container-title":["Critical Reviews in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dl.begellhouse.com\/download\/article\/5d757d032ed34d11\/CRI-60654.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:32:04Z","timestamp":1790793124000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dl.begellhouse.com\/journals\/2ff21abf44b19838,3cd8f7141fb7b275,5d757d032ed34d11.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1615\/critrevimmunol.2025060654","relation":{},"ISSN":["1040-8401"],"issn-type":[{"value":"1040-8401","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]}}}